ONC: BeiGene Operating Margin

Corporate emblem and logo of BeiGene Ltd. (ONC)

BeiGene Ltd (ONC) price action is constrained by high R&D expenditures and dependence on regulatory verdicts. However, the company effectively monetizes Brukinsa, combining Asian cost efficiencies with premium Western markets. Global reach is expanding through partnerships with industry behemoths. Operating profit margins demonstrate a current trend, where the 17.80 mark reflects fresh data on the core business's profitability.

ONC - BeiGene Operating Profit Rate over the range 07/04/2022 - 11/19/2026

Financial and market metric breakdowns for BeiGene Ltd (ONC)

- price and consensus price forecast:
General company analysis:ONC, beigene.com
Brand item of BeiGene Oncology

Operating margin measures the share of profit from core operations before financial expenses and taxes, reflecting cost management efficiency and internal business profitability. Regular monitoring of the operating margin confirms the resilience of BeiGene Ltd. (ONC), as stable demand for therapy within the defensive oncology pharmaceutical sector offsets economic cycles and ensures a predictable cash flow.

Competitors of BeiGene Ltd

Operating Sales Margin HALO|Operating Profitability RVMD|Operating Sales Margin AAPG (Ascentage)|Operating Sales Margin cgoncology.com CGON|UroGen Pharma - Operating Sales Margin|Operating Profit Rate BCAX|PSNL - Operating Profitability|Profitability of Operations Erasca Oncology ERAS|delcath.com (DCTH) - Operating Profitability|Y-mAbs Therapeutics - Operating Profit Rate|AURA (Aura Biosciences Inc) - Operating Margin|Operating Return on Sales candeltx.com CADL|Operating Margin ARAY|SLS (SELLAS Life Sciences Group, Inc.) - Operating Profit Rate|Operating Profitability Actuate Therapeutics, Inc. ACTU|citiusonc.com - Operating Profitability|TuHURA Biosciences Inc. - Operating Margin|TARA - Operating Margin|FATE (Fate Therapeutics) - Operating Sales Margin|Operating Sales Margin Aadi Bioscience, Inc.|Operating Sales Margin TCRX|Operating Profitability CSBR|Operating Margin XBIT|Profitability of Operations CEL-SCI Corp.|Operating Profitability ostherapies.com OSTX|RADX: Return on Sales by Operating Profit|ARTV: Operating Sales Margin|ANL (Adlai Nortye) - Return on Sales by Operating Profit|Veru (VERU) - Operating Profitability|Operating Sales Margin Tempest Therapeutics Inc|Operating Profitability Xilio Therapeutics|Return on Sales by Operating Profit RENB (Renovaro Inc.)|Operating Profitability Mural Oncology PLC (MURA)|Operating Margin Kairos Pharma (KAPA)|Operating Profitability onkuretherapeutics.com OKUR|GDTC: Return on Sales by Operating Profit|CRIS: Operating Sales Margin|apollomicsinc.com (APLM) - Operating Sales Margin|THAR: Operating Margin|Operating Sales Margin Advanced Biomed Inc.|Operating Sales Margin GNPX|Return on Sales by Operating Profit CLDI (Calidi Biotherapeutics)|Operating Margin SBFM|Xenetic Biosciences, Inc. - Return on Sales by Operating Profit|Operating Profitability Salarius Pharmaceuticals SLRX|Operating Margin purple-biotech.com PPBT|AONC - Operating Profitability|BGNE: Operating Profitability|CKPT: Operating Margin|Elevation Oncology - Operating Profit Rate|ICAD (iCAD) - Operating Margin|IKNA: Operating Profit Rate|Operating Profitability Notable Labs (NTBL)|VIRX (Viracta Therapeutics, Inc.) - Operating Profit Rate|Operating Profitability MorphoSys Corporation MOR|NAYA: Return on Sales by Operating Profit|Ascentage Pharma Group International - Operating Margin